Clinical trial · Interventional
Nadolol for Proliferating Infantile Hemangiomas
Nadolol for Proliferating Infantile Hemangiomas: A Prospective Open Label Study With a Historical Control
NCT01010308CI-TRIAL-00053378completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to explore the efficacy and safety of Nadolol in hemangiomas of infancy. The secondary objective is to assess the feasibility of conducting a randomized controlled trial comparing nadolol with corticosteroids and propranolol.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Infantile Hemangioma | Infantile Hemangioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nadolol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Intervention Group:
- description
- The patients in this study are infants aged 1 month to 1 year of age with head and neck hemangiomas currently causing /or with impending function loss (e.g. vision, airway obstruction, feeding, etc), or hemangiomas currently causing/or with potential for facial disfigurement Infants aged 1 month to 1 year of age with head and neck hemangiomas that received treatment with systemic propranolol in the past 2 years as a control group
- interventionNames
- Drug: Nadolol
- type
- NO_INTERVENTION
- label
- Historical control group
- description
- Ten infants (1-12 months of age) treated with propranolol will be identified from a Dermatology Database. Patients will be considered as controls if they were treated with propranolol before 1 year of age and had digital photography documentation of their hemangioma.
- type
- NO_INTERVENTION
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Month
- Maximum age
- 1 Year
Show eligibility criteria text
Inclusion Criteria: Intervention Group * Infants aged 1 month to 1 year of age with head and neck hemangiomas currently causing /or with impending function loss (e.g. vision, airway obstruction, feeding, etc), or hemangiomas currently causing/or with potential for facial disfigurement. Historical Control Group * Infants aged 1 month to 1 year of age with head and neck hemangiomas that received treatment with systemic propranolol in the past 2 years Angiogenesis Marker Control Group * Infants aged 1 month to 1 year attending dermatology clinic Exclusion Criteria: Intervention Group * Patients with PHACES syndrome (proven) or suspected PHACES (plaque like hemangioma awaiting imaging). * Children with history of hypersensitivity to beta blockers * Children with personal history or family history of a first degree relative with asthma * Children with known renal impairment * Children with known cardiac conditions which may predispose to heart blocks * Personal history of hypoglycemia * Children on medications that may interact with beta blockers Historical Control Group: * No digital photography available documenting IHs progression Angiogenesis Marker Control Group: * Children with IH * Children on beta blocker or systemic corticosteroids
References
Publications (0)
Data not yet available
No reference posted for this study.